Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,868 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: DEXAMETHASONE Clear all
Active, not recruiting Phase 3 Interventional

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

NCT03020030
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
Pegaspargase, Erwinia asparaginase, Cyclophosphamide, CYTARABINE, DASATINIB, DEXAMETHASONE, Dexrazoxane, Doxorubicin, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, NELARABINE, Vincristine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2034
U.S. locations
7
States / cities
Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 1 Interventional

Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma

NCT02792036
View directory record Official record
Conditions
Retinoblastoma
Interventions
Carboplatin, Maxitrol®, Focal Therapy, Plaque Radiotherapy
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 23, 2026, 5:44 PM EDT
Active, not recruiting Phase 2 Interventional

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
Drug · Biological
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Davis, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Recruiting Phase 2 Interventional

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

NCT05896228
View directory record Official record
Conditions
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions
Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen, Diphenhydramine, Montelukast
Drug
Lead sponsor
Benjamin T Diamond, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

NCT03500445
View directory record Official record
Conditions
Myeloma, Multiple Myeloma
Interventions
Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma

NCT00166439
View directory record Official record
Conditions
Lymphoma
Interventions
Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)
Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

NCT00437229
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) Oral Tablets, dexamethasone, ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)

NCT06172257
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone ophthalmic suspension (OCS-01), Vehicle
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years to 85 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
42
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer

NCT00446030
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Docetaxel, Doxorubicin, Carboplatin, Cyclophosphamide, Trastuzumab, Bevacizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

NCT02046070
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cyclophosphamide, Ixazomib, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Hazard, Kentucky • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 23, 2026, 5:44 PM EDT
Terminated Phase 4 Interventional Results available

Comparison of Dexamethasone Oral Preparations to Assess Taste and Acceptance in Children With Asthma and Croup

NCT03705273
View directory record Official record
Conditions
Asthma, Croup
Interventions
Dexamethasone IV for PO, Dexamethasone crushed tablets
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Year to 7 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 23, 2026, 5:44 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

NCT05634369
View directory record Official record
Conditions
Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed
Interventions
GEM/DOX + TGFBi expanded NK cells
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
South Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Recruiting Phase 4 Interventional

The Effect of Multimodal Pain Regimen on Use of Narcotics After Rotator Cuff Tear Repair

NCT07076069
View directory record Official record
Conditions
Rotator Cuff Repairs, Pain Management
Interventions
Multimodal Pain Regimen, Standard of Care Pain Regimen
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

NCT04300556
View directory record Official record
Conditions
Solid Tumor
Interventions
Farletuzumab ecteribulin, Prednisone, Prednisolone, Dexamethasone, Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Recruiting Phase 3 Interventional

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

NCT07285239
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years to 79 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma

NCT00580372
View directory record Official record
Conditions
Multiple Myeloma
Interventions
VAD, High-Dose cyclophosphamide, Hemopoietic stem cell procurement, EDAP, Autologous Hemopoietic Stem Cell Transplant 1, Autologous Hemopoietic Stem Cell Transplant 2, Maintenance
Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 23, 2026, 5:44 PM EDT
Terminated Phase 2 Interventional Results available

Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate

NCT00084864
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, dexamethasone, clinical observation
Dietary Supplement · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT00048230
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bortezomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
39
States / cities
Berkeley, California • Duarte, California • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

NCT00057564
View directory record Official record
Conditions
Multiple Myeloma
Interventions
A (Thalidomide + Dexamethasone), B (Placebo + Dexamethasone)
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
26
States / cities
Hoover, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2015 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia

NCT00462787
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, clofarabine, dexamethasone, thiotepa, topotecan hydrochloride, vinorelbine tartrate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 28 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 23, 2026, 5:44 PM EDT
Terminated Phase 1 Interventional

A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies

NCT02223598
View directory record Official record
Conditions
Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma
Interventions
CB-5083, Dexamethasone
Drug
Lead sponsor
Cleave Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Duarte, California • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 23, 2026, 5:44 PM EDT
Terminated Phase 1 Interventional

Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy

NCT00769093
View directory record Official record
Conditions
Brain Neoplasms
Interventions
Ferumoxytol
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 23, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

NCT00806819
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
40
States / cities
Downy, California • Fountain Valley, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 23, 2026, 5:44 PM EDT
Terminated Phase 1 Interventional Results available

First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone

NCT04075721
View directory record Official record
Conditions
Multiple Myeloma
Interventions
M3258, M3258 20 mg
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 23, 2026, 5:44 PM EDT